• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

AbbVie Appears Ready to Start a New Advance at Any Time

Traders should still be long and looking for higher highs. Let's check the charts and indicators again.
By BRUCE KAMICH
Feb 14, 2018 | 01:58 PM EST
Stocks quotes in this article: ABBV

AbbVie Inc. (ABBV) was reviewed a few days ago and I was bullish projecting "that a triple from the $60 base or $180 is the next possible upside price target. Longs should probably raise their sell stop protection to a close below $100." Prices have corrected this month with the broad market weakness but our suggested stop point has not been reached. Traders should still be long and looking for higher highs. Let's check the charts and indicators again.

In this daily bar chart of ABBV, below, we can see that prices have pulled back modestly after their late January strength. Prices successfully tested the rising 50-day moving average line.

The On-Balance-Volume (OBV) line has been moving higher the past year and signals more aggressive buying with heavier turnover on days when the stock has closed higher. The Moving Average Convergence Divergence (MACD) oscillator has crossed to a take profits sell signal but this could be reversed in the days ahead if ABBV rallies again.

In this weekly bar chart of ABBV, below, we find no bearish signals. Prices are above the rising 40-week moving average line. The weekly OVC line has been rising since late 2016 and only shows a small dip currently. The weekly MACD oscillator is bullish but the two moving average lines that make up this indicator have begun to narrow.

In this Point and Figure chart of ABBV, below, we can see the current sideways consolidation pattern. A rally above $116.52 would improve the chart and a decline below $105.49 may produce some selling. A $98.79 price target is shown but I do not anticipate it will be reached.

Bottom line: The trend is still up for ABBV so surprises, if there are any, are likely to be in the direction of the trend. I continue to favor the upside of ABBV and closes above $115 and $116 could be enough to spark a new leg higher.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

Broad Rally, Vaccine Optimism, Johnson & Johnson, GameStop Roars, Trading Nvidia

Stephen Guilfoyle
Feb 25, 2021 7:04 AM EST

The market's catalyst had everything to do with the virus... optimism that humankind might stuff that scourge back into Pandora's box.

Eli Lilly Is Poised for a Pullback Before Renewed Longer-Term Gains

Bruce Kamich
Feb 23, 2021 7:43 AM EST

Let's review the charts and indicators.

It's an Opportune Time to Renew Your Vows With CVS Health

Paul Price
Feb 18, 2021 7:00 AM EST

The pharmacy giant offered a great buy/write options play last summer and is setting up again for such action.

Just Had My First Teladoc Appointment: Is the Rally Over?

Bruce Kamich
Feb 17, 2021 2:39 PM EST

I may be late to trends, but not to stock charts.

CVS Health Reports Q4, and Here's What I'm Changing Up

Stephen Guilfoyle
Feb 16, 2021 10:55 AM EST

I do want to give new CEO Karen Lynch a chance. Nothing against Larry Merlo but I always thought that this stock was undervalued.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:31 PM EST PETER WILLSON

    Has the Short-Term Top Come for the XLF/Banks?

    The has triggered a long-term overbought signal ...
  • 10:10 AM EST GARY BERMAN

    DLTR: The Buck Might Not Stop Here, but I Am Looking for a Bounce

    Dollar Tree is trading inside our long-term boun...
  • 08:36 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 2/24/2021

    SPX (Long-Term View) The 2/16 HIGH @ 3950.43 is ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login